Patient reported outcomes in systemic vasculitis

Area of Science:

• Rheumatology
• Clinical Outcomes Assessment

Background:

• Systemic vasculitis impacts health-related quality of life (HRQOL).
• Generic Patient-Reported Outcomes (PROs) like SF-12, SF-36, and EQ-5D have been utilized across various vasculitis types.
• These include giant cell arteritis, antineutrophil cytoplasmic antibody (ANCA)-related vasculitis, and immunoglobulin A vasculitis.

Purpose of the Study:

• To review the application of PROs in systemic vasculitis.
• To examine the growing integration of PROs in evaluating clinical outcomes and healthcare.
• To highlight the evolution from generic to disease-specific PROs.

Main Methods:

• Review of existing literature on PROs in systemic vasculitis.
• Analysis of the development and application of generic and disease-specific PROs.
• Discussion of emerging trends, including electronic PROs.

Main Results:

• Generic PROs provide a broad assessment of HRQOL in vasculitis.
• Disease-specific PROs, such as AAV-PRO and GCA-PRO, offer targeted evaluation of symptom impact.
• Electronic PROs are emerging as a significant area of interest, accelerated by virtual healthcare models.

Conclusions:

• Both generic and disease-specific PROs are valuable and complementary in managing vasculitis.
• Disease-specific PROs enhance the understanding of treatment effects on patient HRQOL.
• The future of PROs in vasculitis likely involves expanded use of electronic measures.